Insights
The NICE Health Technology Evaluation Manual: A Fresh Perspective Needed?
16 March 2022
This blog post is the fourth in a series on the new National Institute for Health and Care Excellence (NICE) health technology evaluation manual. Each post…
Including Carer Quality of Life in Health Technology Evaluation: Are We There Yet?
10 March 2022
Carer quality of life impacts can be included in health technology evaluations, however little guidance is provided. NICE considered providing more guidance as part of their…
No Smoking Day 2022: Reflecting on OHE Projections from 1994
9 March 2022
Since 1984, the UK’s second Wednesday of each March is NO SMOKING DAY (NSD). The NSD aims to encourage smokers who want to quit. In 2022,…
To Hell with the 3L! NICE’s Missed Opportunity to Upgrade Health Outcome Measurement
2 March 2022
This blog post is the second in a series on the new National Institute for Health and Care Excellence (NICE) health technology evaluation manual. Each post…
Rare Disease Day 2022
28 February 2022
World Rare Disease Day aims to raise awareness of rare diseases and the impact they can have on patients. This blog explores OHE’s contributions to research…
New NICE Manual for Health Technology Evaluations: A Critical Discussion on the Most Relevant Changes (or Lack Thereof)
23 February 2022
OHE opens a series of blog posts on the NICE new health technology evaluation manual. The blogs will provide a critical discussion around the topics, including the…
How Does Pharmaceutical Spending Drive Innovation in Europe?
7 February 2022
A new publication by Kourouklis and Gandjour (2022) investigates the impact of pharmaceutical spending on domestic early-stage pharmaceutical innovation in Europe. They find that European spending…
OHE Critique of CBO’S Pharmaceutical Investment Model Provides Warning for Policymakers on Reliability of Estimates
3 December 2021
As US policymakers consider the potential implications of the drug pricing reforms contained within the Build Back Better Act, OHE releases a critique of the Congressional Budget Office scoring, demonstrating that the estimates are highly uncertain and policymakers should exercise caution when relying upon them.
Does the New CBO Report Change Anything?
15 September 2021
Since we began our project to consult experts on the impact of H.R. 3. on pharmaceutical innovation the CBO has released a new working paper. Given…